Are GLP-1 weight-loss drugs safe for older adults?, AAMC (2025) FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight, Food and Drug Administration (2024) Health risks of overweight and obesity, National Institute of Diabetes and Digestive and Kidney Diseases (2023) Rybelsus, Novo Nordisk Semaglutide injection (weight management), Cleveland Clinic Semaglutide (subcutaneous route), Mayo Clinic U.S
Drug delivery platforms that "reuse" already well-known active pharmaceutical ingredients, such as semaglutide, can rely on existing safety data, which only needs to be supplemented with safety data for the platform itself
Possible drug interactions include: Alcohol may increase the risk of lactic acidosis (Janumet) Carbonic anhydrase inhibitors such as topiramate, zonisamide, acetazolamide or dichlorphenamide may increase the risk of lactic acidosis (Janumet) Digoxin (Januvia) Insulin may increase the risk of low blood sugar (Januvia and Janumet) Share This Page: Who Am I Calling
The warehouse retailer is now offering its U.S
Retatrutide An emerging triple agonist (GLP1, GIP, and glucagon receptors) currently under active study and not FDA-approved for weight loss or general wellness